Michael Stirling
Family · Little Rock, ARNPI 1306338413
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 50 manufacturers reported payments, led by Acerus Pharmaceuticals Corporation at 31.0% of the total. Reporting peaked in 2022 at $10,906 and has fallen 82.5% since, to $1,909 in 2025. Among family clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 454 payments — averaging $50.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acerus Pharmaceuticals Corporation$7K
- Novo Nordisk$5K
- Boston Scientific$931
- Dexcom, Inc.$830
- AstraZeneca$776
- Amgen$743
- plus $7K from 44 others
What the payments were for
- Consulting fees$6,09927%
- Speaking & faculty fees$2,1459%
- Travel & lodging$4,15318%
- Food & beverage$10,37645%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Natesto$7,086
- Rivfloza$829
- AMS 700 CXR RTE KIT$808
- Strensiq$420
- myRisk$358
- FreeStyle Libre$270
- DEXCOM G6 TRANSMITTER$247
- PROVENGE$155
- ANGIO-SEAL$140
- Azur CX Detachable$140
- NEXLIZET$124
- NEXLETOL$124
- RYBELSUS$122
- Kerendia$121
- EVENITY$116
- Wegovy$115
- INPEN SMART INSULIN DELIVERY SYSTEM$111
- Prolia$109
- MOUNJARO$108
- XIAFLEX$108
How this compares
$22,875 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 18 | $243,725 |
| MyrbetriqMirabegron | 49 | $31,979 |
| GemtesaVibegron | 24 | $20,438 |
| Testosterone Cypionate | 238 | $10,560 |
| Tamsulosin Hcl | 507 | $7,834 |
| Oxybutynin Chloride ErOxybutynin Chloride | 146 | $2,293 |
| Finasteride | 168 | $2,047 |
| Testosterone | 18 | $1,785 |
| Trospium Chloride | 37 | $1,571 |
| Dutasteride | 57 | $1,347 |
| Solifenacin Succinate | 20 | $801 |
| Ciprofloxacin Hcl | 64 | $583 |
| Megestrol Acetate | 17 | $550 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $325 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 36 | $182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $26 | $275,70467 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $61 | $20,43824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.
Other family in Little Rock
- Anthony EcholsLittle Rock$25K
- Emily AllenLittle Rock$14K
- Brandy EasonLittle Rock$13K
- Matthew TaylorLittle Rock$10K
- Collene RogersLittle Rock$9K
- Morgan BittengleLittle Rock$9K
- Melissa BaldwinLittle Rock$8K
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.